K S Slobod
Overview
Explore the profile of K S Slobod including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
254
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brown S, Slobod K, Surman S, Zirkel A, Zhan X, Hurwitz J
AIDS Res Hum Retroviruses
. 2006 Feb;
22(2):188-94.
PMID: 16478402
HIV-1 vaccines are often designed to target one or several virus subtype(s). They therefore include antigens (e.g., env or env/gag/pol) from each targeted subtype to elicit subtype-directed immunity. To determine...
2.
Stambas J, Brown S, Gutierrez A, Sealy R, Yue W, Jones B, et al.
Vaccine
. 2005 Mar;
23(19):2454-64.
PMID: 15752831
Despite decades of work, an effective HIV vaccine remains elusive. In an effort to elicit protective immunity, investigators have sought to define vaccines able to elicit durable HIV-specific B-cell and...
3.
Slobod K, Lockey T, Howlett N, Srinivas R, Rencher S, Freiden P, et al.
Eur J Clin Microbiol Infect Dis
. 2004 Jan;
23(2):106-10.
PMID: 14735404
A critical goal of HIV vaccine development is the identification of safe and immunogenic vectors. Recombinant vaccinia virus is a highly effective vaccine vector, with demonstrated capacity to protect animals...
4.
Zhan X, Slobod K, Surman S, Brown S, Lockey T, Coleclough C, et al.
J Virol
. 2003 Mar;
77(7):4231-6.
PMID: 12634380
Single-envelope human immunodeficiency virus (HIV) vaccines have been studied for more than a decade, with some successes in homologous challenge experiments in nonhuman primates but with no clear successes in...
5.
Slobod K, Benaim E, Woodruff L, Nooner S, Houston J, Holladay M, et al.
Immunol Res
. 2002 Jan;
24(3):289-301.
PMID: 11817326
Immunotherapies designed to prevent infection serve as an increasingly important adjunct to bone marrow transplantation (BMT). T cell immunotherapies are particularly useful for the control of virus infections, provided that...
6.
DCosta S, Slobod K, Benaim E, Bowman L, Cunningham J, Holladay M, et al.
Bone Marrow Transplant
. 2001 Oct;
28(6):573-80.
PMID: 11607770
Allogeneic bone marrow transplantation (BMT) is an effective therapy for a variety of malignancies and blood disorders, but rarely serves as a frontline treatment because of numerous, potential complications. Important...
7.
DCosta S, Slobod K, Webster R, White S, Hurwitz J
AIDS Res Hum Retroviruses
. 2001 Aug;
17(12):1205-9.
PMID: 11522189
Two neutralizing antibodies specific for the V3 sequence of HIV envelope were used to generate escape variants from the HTLV(IIIB) founder virus. The full gp120 sequence of each variant was...
8.
Surman S, Lockey T, Slobod K, Jones B, Riberdy J, White S, et al.
Proc Natl Acad Sci U S A
. 2001 Apr;
98(8):4587-92.
PMID: 11287644
The spectrum of immunogenic epitopes presented by the H2-IA(b) MHC class II molecule to CD4(+) T cells has been defined for two different (clade B and clade D) HIV envelope...
9.
Shenep J, Flynn P, Baker D, Hetherington S, Hudson M, Hughes W, et al.
Clin Infect Dis
. 2000 Dec;
32(1):36-43.
PMID: 11112678
Empiric oral antibiotic therapy for febrile neutropenic cancer patients has been suggested as a means to decrease hospitalization, but the safety of this approach has not been adequately studied in...
10.
Slobod K, TAYLOR G, Sandlund J, Furth P, Helton K, Sixbey J
Lancet
. 2000 Nov;
356(9240):1493-4.
PMID: 11081539
Epstein-Barr virus (EBV) targeted therapeutic strategies for viral associated malignant diseases have received only perfunctory consideration, first, because latent herpesviruses have been intractable to antiviral chemotherapy and, second, because the...